$Recursion Pharmaceuticals, Inc.(RXRX)$
โ๏ธ๐ ๐ ฑ๏ธ แนฒฬฎ Lฬคฬฎ Lฬคฬฎ Iฬคฬฎ Sฬคฬฎ Hฬคฬฎ๐โ๏ธโ๏ธ $RXRX is trying to move on up, ๐ฏ Q1 $16โ
ARK Investment Management LLC raised its holdings in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company's stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Lingotto Investment Management LLP raised its stake in shares of Recursion Pharmaceuticals by 69.0% in the second quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company's stock worth $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $8,250,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the second quarter valued at approximately $5,769,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Happy trading aheadโฃ๏ธ Cheers BC ๐ฐ๐๐๐๐๐
@Tiger_comments @Daily_Discussion @TigerPicks @TigerStars @TigerPM @TigerGPT
Modify on 2024-12-27 01:04
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Company Profile: Recursion Pharmaceuticals, Inc. (RXRX)
Stock Name: Recursion Pharmaceuticals, Inc. (RXRX)
Stock Code: RXRX
Established Year: 2013
Address: 41 South Rio Grande Street, Salt Lake City, Utah, United States
Post Code: 84101
Telephone: 385 269 0203
Fax: 801 821 2872
Currency Type: USD
Business Type: Clinical-stage biotechnology company
Employee Number: 500
Executive Information:
Chief Executive Officer, Director: Christopher Gibson (Male, Age 38)
Chief Operating Officer, President: Tina Marriott Larson (Female, Age 46)
Chief Financial Officer: Michael Secora (Male, Age 38)
Chief Corporate Development Officer: Shafique Virani (Male, Age 50)
Director Information:
Chief Executive Officer, Director: Christopher Gibson
Chair of the Board: R. Martin Chavez
Director: Blake Borgeson
Director: Dean Li
Director: Robert M. Hershberg
Shareholder Information:
ARK Investment Management LLC:
Number of Shares: 32.77 million
Shareholding Ratio: 11.42%
Change in Shares: 0.0
Baillie Gifford & Co.:
Number of Shares: 25.24 million
Shareholding Ratio: 8.80%
Change in Shares: 0.0
The Vanguard Group, Inc.:
Number of Shares: 24.27 million
Shareholding Ratio: 8.46%
Change in Shares: 0.0
BlackRock, Inc.:
Number of Shares: 20.74 million
Shareholding Ratio: 7.23%
Change in Shares: 0.0
Nikko Asset Management Co., Ltd.:
Number of Shares: 19.46 million
Shareholding Ratio: 6.78%
Change in Shares: 0.0
Business Operating Income:
As of 2024Q3: Information not provided
Proportion of Business Revenue:
As of 2024Q3: Information not provided
Total Share Capital:
Date: 2024-12-27
Value: 391.00M
Float Share Capital:
Date: 2024-12-27
Value: 356.00M
Company Profile:Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engaging in the decoding of biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company's therapeutic pipeline includes various candidates in different stages of development for the treatment of cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, Clostridioides difficile infection, AXIN1 or APC mutant cancers, HR-proficient ovarian cancer, immune checkpoint resistance, and improving sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. Recursion Pharmaceuticals has collaborations and agreements with leading pharmaceutical companies and research institutions.
For more detailed information about Recursion Pharmaceuticals, you can visit their website.
Relevant Articles:
๐ฅShare your strategy for making money on the market!
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
BRIEF-Recursion Pharmaceuticals Inc - Files Prospectus Supplement
Stock Track | Recursion Pharmaceuticals Pre-Market Soars 5.09% on Promising Developments and Positive Analyst Outlook
Cautious Optimism for Recursion Pharmaceuticals Amid Promising Safety Profile and Upcoming Milestones
Recursion Pharmaceuticals (RXRX) Bold Acquisition Places it as an Industry Leader
Please note that the provided information is for reference purposes only and does not constitute investment advice.
Let me know if there's anything else I can assist you with.
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?
Great article, would you like to share it?